Claims:

1. Use of at least one macrocyclic lactone or a salt, hydrate, solvate, tautomer or stereoisomer thereof for the manufacture of a medicament for the prevention, inhibition or treatment of a coronavirus infection, or for reducing the risk of acquiring a coronavirus infection, or for preventing antibody dependent enhanced (ADE) coronavirus infection in a subject, wherein the at least one macrocyclic lactone is ivermectin, moxidection, or both ivermectin and moxidectin.

2. The use of claim 1, wherein the level of detectable coronavirus in the subject is reduced by at least 50%.

3. The use of claim 1, wherein the level of detectable coronavirus in the subject is reduced by at least 70%.

4. The use of claim 1, wherein the level of detectable coronavirus in the subject is reduced by at least 80%.

5. The use of claim 1, wherein the level of detectable coronavirus in the subject is reduced by at least 90%.

6. The use of claim 1, wherein the level of detectable coronavirus in the subject is reduced by at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9%.

7. The use of any one of claims 1 to 6, wherein the level of detectable coronavirus is reduced over a period of 1, 2, 3, or more days after administration of the macrocyclic lactone or a salt, hydrate, solvate, tautomer or stereoisomer thereof.

8. The use of any one of claims 1 to 6, wherein the level of detectable coronavirus in the human subject over a period of 1 to 3 days after administration of the macrocyclic lactone or a salt, hydrate, solvate, tautomer, or stereoisomer thereof.

9. The use of any one of claims 1 to 8, wherein the subject is a human.

10. The use of any one of claims 1 to 9, wherein the coronavirus is coronavirus 229E, coronavirus NL63, coronavirus OC43, SARS-CoV, MERS-CoV, SARS-CoV-2, or variants thereof.

11. The use of claim 10 wherein the coronavirus is SARS-CoV-2 or a SARS-CoV-2 variant.

12. The use of any one of claims 1 to 11, wherein the at least one macrocyclic lactone is to be administered at a dose of 0.1 mg/kg to 1.0 mg/kg body weight of the subject.